Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;86(1014):208-11.
doi: 10.1136/pgmj.2009.085787.

Clinical experience of methotrexate in Crohn's disease: response, safety and monitoring of treatment

Richard Parker  1 , Anindya Dixit, Aileen Fraser, Tom J Creed, Chris S Probert
Affiliations

Clinical experience of methotrexate in Crohn's disease: response, safety and monitoring of treatment

Richard Parker et al. Postgrad Med J. 2010 Apr.

Erratum in

  • Postgrad Med J. 2011 Mar;87(1025):242. Dixit, Anyinda [corrected to Dixit, Anindya]

Abstract

Background: Methotrexate is an immunosuppressant used in the treatment of patients with Crohn's disease who are intolerant or refractory to azathioprine.

Aim: To present clinical experience in terms of response, side effects and reason for cessation of methotrexate treatment as well as adherence to monitoring regimens.

Design: Retrospective review of case records of 37 patients taking methotrexate for Crohn's disease at the Bristol Royal Infirmary, a large UK teaching hospital. Thirty-five patients used oral methotrexate.

Results: Response rate to methotrexate was 78% at 3 months. Adverse events were uncommon and rarely dangerous. Monitoring of treatment did not adhere to British Society of Gastroenterology guidelines.

Conclusion: Oral methotrexate is effective and safe in the treatment of Crohn's disease. This is in contrast to findings of previous series, which have mainly reported on intramuscular methotrexate use. Monitoring of treatment is currently inadequate and consensus should be sought for a pragmatic monitoring schedule to resolve this important governance issue.

PubMed Disclaimer